On March 2, 2026 Black Diamond Therapeutics, Inc. (Nasdaq: BDTX), a clinical-stage oncology company developing MasterKey therapies that target families of oncogenic mutations in patients with cancer, reported its participation in upcoming investor conferences. Presentation details with President and Chief Executive Officer, Mark Velleca, M.D., Ph.D. and Chief Scientific Officer Elizabeth Buck, Ph.D., are as follows:

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

46th Annual TD Cowen Healthcare Conference presentation at 1:10pm ET on Wednesday, March 4, 2026
25th Annual Needham Virtual Healthcare Conference presentation at 3:00pm ET on Wednesday, April 15, 2026

Webcasts will be available at the start of the presentations on the investor relations section of the Company’s website, www.blackdiamondtherapeutics.com. Replays of the presentations will also be available and archived on the site for 90 days. The Company will also meet with investors at the Raymond James BioPharma Conference on Tuesday, April 14, 2026.

(Press release, Black Diamond Therapeutics, MAR 2, 2026, View Source [SID1234663170])